vs

Side-by-side financial comparison of SUNation Energy, Inc. (SUNE) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Zymeworks Inc. is the larger business by last-quarter revenue ($27.6M vs $27.2M, roughly 1.0× SUNation Energy, Inc.). SUNation Energy, Inc. runs the higher net margin — 9.6% vs -71.0%, a 80.6% gap on every dollar of revenue. On growth, SUNation Energy, Inc. posted the faster year-over-year revenue change (77.0% vs 72.6%).

Suncor Energy Inc. is a Canadian integrated energy company based in Calgary, Alberta. It specializes in production of synthetic crude from oil sands. In the 2020 Forbes Global 2000, Suncor Energy was ranked as the 48th-largest public company in the world.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

SUNE vs ZYME — Head-to-Head

Bigger by revenue
ZYME
ZYME
1.0× larger
ZYME
$27.6M
$27.2M
SUNE
Growing faster (revenue YoY)
SUNE
SUNE
+4.4% gap
SUNE
77.0%
72.6%
ZYME
Higher net margin
SUNE
SUNE
80.6% more per $
SUNE
9.6%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
SUNE
SUNE
ZYME
ZYME
Revenue
$27.2M
$27.6M
Net Profit
$2.6M
$-19.6M
Gross Margin
40.7%
Operating Margin
10.7%
-80.1%
Net Margin
9.6%
-71.0%
Revenue YoY
77.0%
72.6%
Net Profit YoY
138.2%
34.3%
EPS (diluted)
$105.59
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SUNE
SUNE
ZYME
ZYME
Q4 25
$27.2M
Q3 25
$19.0M
$27.6M
Q2 25
$13.1M
$48.7M
Q1 25
$12.6M
$27.1M
Q4 24
$15.4M
$31.0M
Q3 24
$14.7M
$16.0M
Q2 24
$13.5M
$19.2M
Q1 24
$13.2M
$10.0M
Net Profit
SUNE
SUNE
ZYME
ZYME
Q4 25
$2.6M
Q3 25
$-393.0K
$-19.6M
Q2 25
$-9.6M
$2.3M
Q1 25
$-3.5M
$-22.6M
Q4 24
$-6.8M
$-23.5M
Q3 24
$-3.3M
$-29.9M
Q2 24
$-6.9M
$-37.7M
Q1 24
$1.2M
$-31.7M
Gross Margin
SUNE
SUNE
ZYME
ZYME
Q4 25
40.7%
Q3 25
38.0%
Q2 25
37.0%
Q1 25
35.1%
Q4 24
36.4%
Q3 24
35.6%
Q2 24
35.4%
Q1 24
36.4%
Operating Margin
SUNE
SUNE
ZYME
ZYME
Q4 25
10.7%
Q3 25
-1.3%
-80.1%
Q2 25
-16.6%
-1.4%
Q1 25
-17.2%
-94.5%
Q4 24
-42.3%
-71.6%
Q3 24
-10.9%
-213.8%
Q2 24
-15.0%
-222.9%
Q1 24
-16.5%
-376.9%
Net Margin
SUNE
SUNE
ZYME
ZYME
Q4 25
9.6%
Q3 25
-2.1%
-71.0%
Q2 25
-73.5%
4.8%
Q1 25
-27.7%
-83.5%
Q4 24
-44.4%
-75.8%
Q3 24
-22.4%
-186.6%
Q2 24
-51.2%
-195.8%
Q1 24
9.1%
-315.6%
EPS (diluted)
SUNE
SUNE
ZYME
ZYME
Q4 25
$105.59
Q3 25
$-0.12
$-0.26
Q2 25
$-3.14
$0.03
Q1 25
$-106.71
$-0.30
Q4 24
$41676.94
$-0.32
Q3 24
$-2350.12
$-0.39
Q2 24
$-11022.91
$-0.49
Q1 24
$-38414.84
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SUNE
SUNE
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$7.2M
$64.8M
Total DebtLower is stronger
$6.6M
Stockholders' EquityBook value
$24.3M
$320.1M
Total Assets
$48.2M
$397.3M
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SUNE
SUNE
ZYME
ZYME
Q4 25
$7.2M
Q3 25
$5.4M
$64.8M
Q2 25
$3.2M
$98.3M
Q1 25
$1.4M
$76.2M
Q4 24
$839.3K
$66.1M
Q3 24
$1.1M
$122.4M
Q2 24
$1.0M
$71.0M
Q1 24
$1.8M
$114.8M
Total Debt
SUNE
SUNE
ZYME
ZYME
Q4 25
$6.6M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
SUNE
SUNE
ZYME
ZYME
Q4 25
$24.3M
Q3 25
$21.7M
$320.1M
Q2 25
$22.1M
$334.5M
Q1 25
$14.8M
$325.0M
Q4 24
$8.5M
$338.8M
Q3 24
$13.1M
$367.0M
Q2 24
$-10.9M
$406.2M
Q1 24
$-11.2M
$438.0M
Total Assets
SUNE
SUNE
ZYME
ZYME
Q4 25
$48.2M
Q3 25
$49.6M
$397.3M
Q2 25
$44.1M
$408.4M
Q1 25
$44.4M
$425.5M
Q4 24
$45.7M
$463.1M
Q3 24
$51.0M
$487.2M
Q2 24
$52.9M
$515.6M
Q1 24
$54.7M
$553.8M
Debt / Equity
SUNE
SUNE
ZYME
ZYME
Q4 25
0.27×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SUNE
SUNE
ZYME
ZYME
Operating Cash FlowLast quarter
$2.1M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
0.81×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SUNE
SUNE
ZYME
ZYME
Q4 25
$2.1M
Q3 25
$2.4M
$-31.4M
Q2 25
$-130.2K
$12.1M
Q1 25
$-3.4M
$-3.4M
Q4 24
$-1.9M
$-41.5M
Q3 24
$-968.1K
$-5.9M
Q2 24
$-776.4K
$-25.0M
Q1 24
$-2.6M
$-37.7M
Free Cash Flow
SUNE
SUNE
ZYME
ZYME
Q4 25
Q3 25
$2.4M
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-1.9M
$-41.8M
Q3 24
$-980.3K
$-6.8M
Q2 24
$-788.4K
$-25.6M
Q1 24
$-2.7M
$-37.9M
FCF Margin
SUNE
SUNE
ZYME
ZYME
Q4 25
Q3 25
12.5%
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-12.4%
-134.8%
Q3 24
-6.7%
-42.4%
Q2 24
-5.8%
-133.0%
Q1 24
-20.1%
-377.5%
Capex Intensity
SUNE
SUNE
ZYME
ZYME
Q4 25
Q3 25
0.0%
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
0.0%
1.0%
Q3 24
0.1%
5.6%
Q2 24
0.1%
3.1%
Q1 24
0.0%
1.8%
Cash Conversion
SUNE
SUNE
ZYME
ZYME
Q4 25
0.81×
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-2.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SUNE
SUNE

Transferred At Point In Time$15.1M55%
Hawaii Energy Connection$10.0M37%
Transferred Over Time$2.1M8%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons